Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties

Timothy A. Esbenshade, Gerard B. Fox, Kathleen M. Krueger, Thomas R. Miller, Chae Hee Kang, Lynne I. Denny, David G. Witte, Betty B. Yao, Liping Pan, Jill Wetter, Kennan Marsh, Youssef L. Bennani, Marlon D. Cowart, James P. Sullivan and Arthur A. Hancock
Journal of Pharmacology and Experimental Therapeutics April 2005, 313 (1) 165-175; DOI: https://doi.org/10.1124/jpet.104.078303
Timothy A. Esbenshade
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard B. Fox
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Krueger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas R. Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chae Hee Kang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynne I. Denny
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David G. Witte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Betty B. Yao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liping Pan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill Wetter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kennan Marsh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youssef L. Bennani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marlon D. Cowart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James P. Sullivan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur A. Hancock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Histamine H3 receptor antagonists are being developed to treat a variety of neurological and cognitive disorders that may be ameliorated by enhancement of central neurotransmitter release. Here, we present the in vitro pharmacological and in vivo pharmacokinetic profiles for the nonimidazole, benzofuran ligand ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] and compare it with several previously described imidazole and nonimidazole H3 receptor antagonists. ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pKi values of 9.4 and 8.9, respectively, and is over 1000-fold selective versus human H1, H2, and H4 histamine receptors. ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pKb = 7.9 and 7.6, respectively), guanosine 5′-O-(3-[35S]thio) triphosphate ([35S]GTPγS) binding (pKb = 9.0 and 8.3, respectively), and calcium mobilization (human pKb = 7.9). ABT-239 also competitively reversed histamine-mediated inhibition of [3H]histamine release from rat brain cortical synaptosomes (pKb = 7.7) and agonist-induced inhibition of contractile responses in electric field stimulated guinea pig ileal segments (pA2 = 8.7). Additionally, ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPγS binding at both rat and human H3 receptors with respective pEC50 values of 8.9 and 8.2. ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%. Thus, ABT-239 is a selective, nonimidazole H3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties.

Footnotes

  • This work was supported by Abbott Laboratories. Portions of this work were previously presented at the 32nd Annual European Histamine Research Society Meeting, Düsseldorf/Köln, Germany, May 7 to 11, 2003, and at the 33rd Annual Society for Neuroscience Meeting, New Orleans, LA, November 8 to 12, 2003.

  • doi:10.1124/jpet.104.078303.

  • ABBREVIATIONS: CNS, central nervous system; 5-HT, 5-hydroxytryptamine; P450, cytochrome P450; A-304121, 4-(3-((2R)-2-aminopropanoyl-1-piperazinyl)propoxy)phenyl)(cyclopropyl)methanone; A-317920, N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl-)-2-furamide; A-349821, (4′-(3-((R,R)2,5-dimethyl-pyrrolidin-1-yl)-propoxy)-biphenyl-4-yl)-morpholin-4-yl-methanone; ABT-239, 4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile; GTPγS, guanosine 5′-O-(3-[35S]thio)triphosphate; [3H]LY-278584, 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-1H-indazole-3-carboxamide; (R)-α-MeHA, (R)-α-methylhistamine; HEK, human embryonic kidney; EFS, electric field stimulation; LC/MS, liquid chromatography/mass spectrometry.

    • Received September 23, 2004.
    • Accepted December 13, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 2
1 May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties

Timothy A. Esbenshade, Gerard B. Fox, Kathleen M. Krueger, Thomas R. Miller, Chae Hee Kang, Lynne I. Denny, David G. Witte, Betty B. Yao, Liping Pan, Jill Wetter, Kennan Marsh, Youssef L. Bennani, Marlon D. Cowart, James P. Sullivan and Arthur A. Hancock
Journal of Pharmacology and Experimental Therapeutics April 1, 2005, 313 (1) 165-175; DOI: https://doi.org/10.1124/jpet.104.078303

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties

Timothy A. Esbenshade, Gerard B. Fox, Kathleen M. Krueger, Thomas R. Miller, Chae Hee Kang, Lynne I. Denny, David G. Witte, Betty B. Yao, Liping Pan, Jill Wetter, Kennan Marsh, Youssef L. Bennani, Marlon D. Cowart, James P. Sullivan and Arthur A. Hancock
Journal of Pharmacology and Experimental Therapeutics April 1, 2005, 313 (1) 165-175; DOI: https://doi.org/10.1124/jpet.104.078303
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antipsychotic-VMAT2 Inhibitor Synergy: Schizophrenia Models
  • Rescue Pharmacology on Disease-Related GRIN Variants
  • Obesity thwarts preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics